Neurological Biomarkers Market
Neurological Biomarkers Market by Offering (Consumables, Instruments), Type (Proteomic, Genomic), Application (Alzheimer’s, Parkinson’s), End user (Pharma Companies, Clinical Labs) -Global Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The neurological biomarkers market is expected to grow from USD 5.53 billion in 2025 to USD 9.91 billion by 2030, representing a CAGR of 10.7% during this period. Neurological biomarkers are measurable biological characteristics that assist in the diagnosis, characterization, prognosis, and therapeutic management of diseases affecting both the central and peripheral nervous systems.
KEY TAKEAWAYS
-
BY REGIONThe North America neurological biomarkers market had the largest share of 40% in 2024.
-
BY TYPEBy type, the proteomics biomarkers segment is expected to dominate the market with the largest share - 31%.
-
BY APPLICATIONBy application, the Alzheimer's disease segment is expected to have the largest share of 35%.
-
COMPETITIVE LANDSCAPE - KEY PLAYERSAbbott, ThermoFisher Scientific, and Qiagen, were identified as some of the star players in the neurological biomarkers market (global), given their strong market share and product footprint.
-
COMPETITIVE LANDSCAPE - STARTUPS/SMESC2N Diagnostics, DiaGenic ASA, and Unravel biosciences among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The neurological biomarkers market is expanding rapidly, driven by the increasing emphasis on precision neurology, the growing clinical adoption of biomarker-guided diagnosis and treatment, and the rising prevalence of neurological disorders worldwide.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The neurological biomarker field is advancing rapidly, driven by recent advances in genomics, proteomics, and precision medicine in neurodegenerative disorders such as Alzheimer's and Parkinson's. The increasing use of neurological biomarkers for early diagnosis, monitoring of specific neurodegenerative disorders, and the development of targeted drugs are increasing demand for tests of DNA, RNA, and proteins, as well as for specific markers such as neurofilament light chains and phospho-tau. Methodologies such as next-generation sequencing, Simoa tests, and multiplex tests developed by some organizations and pharmaceutical companies are advancing drug development and clinical diagnostics, providing reliable results from validated tests.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Rising prevalence of neurological disorders
-
Increased clinical and regulatory recognition
Level
-
High development costs
Level
-
Digital and computational biomarkers
Level
-
Regulatory and validation barriers
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Rising prevalence of neurological disorders
Increase in the incidence and diagnosis of Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy, stroke, and traumatic brain injury are driving demand for reliable biomarkers to support early diagnosis and disease monitoring.
Restraint: High development costs
The high development costs of assays, imaging procedures, and advanced analytical platforms can restrict adoption, especially in resource-constrained healthcare systems.
Opportunity: Digital and computational biomarkers
The growth of digital health technologies, including wearable sensors, remote monitoring platforms, and AI-driven analytics, is enabling the development of novel digital neurological biomarkers. These solutions support continuous, real-world, and longitudinal assessment of neurological function.
Opportunity: Regulatory and validation barriers
Rigorous analytical and clinical validation requirements for neurological biomarkers significantly extend development timelines and increase regulatory burden. Demonstrating clinical relevance, reproducibility, and longitudinal reliability across heterogeneous patient populations remains complex, slowing biomarker qualification and commercial adoption.
NEUROLOGICAL BIOMARKERS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Immunoassay-based neurological biomarker tests and automated diagnostic platforms used for the detection and monitoring of neurological and neurodegenerative conditions, including traumatic brain injury, neuroinflammation, and neurodegeneration, across hospital and reference laboratory settings | Enables standardized, high-throughput measurement of clinically relevant neurological biomarkers, supports early diagnosis and disease monitoring | Improves workflow efficiency through automation | Facilitates broader clinical adoption of biomarker-driven neurology care |
 |
Advanced immunoassay, multiplex, and digital PCR solutions used in neurological biomarker research and translational applications, including quantification of protein and nucleic acid biomarkers associated with neurodegenerative, neuroinflammatory, and neuromuscular diseases | Supports sensitive and reproducible detection of low-abundance neurological biomarkers, enables multiplexed analysis for comprehensive disease profiling | Accelerates biomarker discovery and validation in academic, pharmaceutical, and clinical research environments |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The neurological biomarkers market is a collaborative network of innovators, testers, labs, drug developers, service experts, and patients. Companies develop ultra-sensitive tools to detect proteins such as neurofilament light chain (NfL) in blood, while others have tests approved to meet rigorous FDA and EMA standards for Alzheimer's and Parkinson's diagnostics. Labs and hospitals put these into practice to pinpoint the right treatments and track progress, while pharma firms and CROs incorporate them into trials to accelerate drug discovery.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Neurological Biomarkers Market, By Offering
Consumables represent the largest share of the neurological biomarkers market due to their essential role in high-volume, routine testing workflows for neuronal damage detection, neurodegeneration monitoring, and neuroinflammation assessment.
Neurological Biomarkers Market, By Type
Proteomic biomarkers represent the largest share of the neurological biomarkers market due to their strong clinical relevance in detecting neuronal damage, neurodegeneration, and neuroinflammation.
Neurological Biomarkers Market, By Application
In 2024, Alzheimer’s disease was the largest application segment, driven by the growing global disease burden and increasing demand for early, accurate diagnosis, the adoption of fluid-based biomarkers for amyloid and tau pathology, and their integration into clinical trials.
Neurological Biomarkers Market, By End User
Pharmaceutical and biotechnology companies constitute the largest end user segment, reflecting extensive use of neurological biomarkers in drug discovery, target validation, patient stratification, and clinical trial optimization.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
During the forecast period, the Asia Pacific region is expected to be the fastest-growing regional market for neurological biomarkers, driven by a rapidly aging population, rising prevalence of neurological disorders, and improving diagnostic infrastructure. Rising government healthcare investments, expanding pharmaceutical and biotechnology R&D activities, and growing adoption of advanced biomarker technologies across China, Japan, India, and Southeast Asia are further accelerating market growth, despite North America retaining the largest overall market share.
NEUROLOGICAL BIOMARKERS MARKET: COMPANY EVALUATION MATRIX
The neurological biomarkers market matrix positions Abbott as a star player, supported by its expanding portfolio of blood-based neurological biomarker assays, strong presence in automated immunoassay platforms, and increasing adoption across clinical laboratories for neurodegenerative and acute neurological conditions. Quanterix is emerging as a key growth leader, leveraging its ultra-sensitive Simoa technology, expanding assay menu for low-abundance neurological proteins, and growing penetration in Alzheimer’s disease research and neurology-focused clinical trials.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- ABBOTT (US)
- THERMO FISHER SCIENTIFIC INC. (US)
- QIAGEN (Germany)
- BIO-RAD LABORATORIES, INC (US)
- MERCK KGaA (Germany)
- JOHNSON & JOHNSON (US)
- QUANTERIX (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 5.16 Billion |
| Market Forecast in 2030 (Value) | USD 9.19 Billion |
| Growth Rate | CAGR of 10.7% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: NEUROLOGICAL BIOMARKERS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Neurological biomarker usage insights | Analyzed use of diagnostic, prognostic, and predictive neurological biomarkers across neurology clinical trials, including preferred modalities, sample types, and testing workflows | Helps vendors target high-value trial phases and align offerings with neurology-focused pharma and CRO needs |
| Sustainability-focused testing roadmap | Evaluated environmental impact of neurological biomarker workflows, including sample types, consumables usage, and adoption of low-impact digital biomarkers | Supports ESG-led positioning through lower-waste and more efficient neurological biomarker solutions |
RECENT DEVELOPMENTS
- October 2025 : Thermo Fisher launched the Olink® Target 48 Neurodegeneration panel—a targeted proteomics immunoassay for plasma/CSF that measures key markers in Alzheimer's, Parkinson's, and MS, delivering reproducible results on the benchtop Signature Q100 system and streamlining research.
- March 2024 : Quanterix earned FDA Breakthrough Device Designation for its Simoa p-Tau 217 blood test, for assessing Alzheimer's risk through cognitive impairment, which paves the way for faster approvals amid surging AD needs.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information to analyze the global neurological biomarkers market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the neurological biomarkers market. The secondary sources used for this study include American Society of Clinical Oncology (ASCO), Canadian Alliance for Healthy Hearts and Minds (CAHHM), Canadian Institute for Health Information (CIHI), Central Drugs Standard Control Organization (CDSCO), Center for Disease Evaluation and Research (CDER), Centers for Disease Control and Prevention (CDC), Chinese Medical Journal, Clinicaltrials.gov.in, European Medicines Agency (EMA), Food and Drug Administration (FDA), GLOBOCAN, International Agency for Research on Cancer (IARC), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), National Comprehensive Cancer Network (NCCN), Organization for Economic Co-operation and Development (OECD), Population Health Research Institute (PHRI), PubMed, World Bank, World Health Organization (WHO), Corporate and Regulatory Filings, Annual Reports, Sec Filings, Investor Presentations, and Financial Statements; Business Magazines & Research Journals; Press Releases, MarketsandMarkets Analysis. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global neurological biomarkers market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & and biotechnology companies, hospitals & diagnostic laboratories, academic & research institutes, and other end users) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, across six major regions—North America, Europe, the Asia Pacific, Latin America, Middle East, and Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This preliminary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the neurological biomarkers market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Bottom-up Approach
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the neurological biomarkers market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
Top-down Approach
- After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
A biomarker is a measurable indicator of a biological condition or process, often used to diagnose diseases, predict disease progression, and evaluate treatment response. Neurological Biomarkers can be molecular, histologic, radiographic, or physiological characteristics that provide valuable insights into normal and pathological processes. The neurological biomarkers market encompasses a broad range of products and services that support biomarker discovery, validation, and application in clinical and research settings. This includes offerings such as consumables (assay kits, reagents, and instruments), software tools, and related services that facilitate biomarker analysis. The market report analyzes biomarker usage across multiple applications, including clinical diagnostics, drug discovery and development, personalized medicine, and clinical research. It also studies the adoption of neurological biomarkers across key research areas, such as oncology, neurology, cardiology, infectious diseases, and metabolic disorders. Furthermore, the report segments the market by type of neurological biomarkers, including safety, efficacy, and validation neurological biomarkers. The study also considers regional trends, end-user adoption, and technological advancements shaping the global biomarker landscape.
Stakeholders
- Academic & Research Institutes
- Neurological Biomarkers Assays and Reagents Manufacturers, Vendors, and Distributors
- Contract Research Organizations (CROs)
- Neurological Biomarkers Service & Software Providers
- Diagnostics Companies
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Contract development and manufacturing organizations (CDMOs)
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the global neurological biomarkers market based on offering, type, research area, technology, disease indication, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro-markets with respect to individual growth trends, prospects, and contributions to the overall market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments in six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global neurological biomarkers market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and collaborations in the neurological biomarkers market
- To benchmark players in the neurological biomarkers market using the “Company Evaluation Matrix” framework, which analyzes market players based on various parameters, including product portfolio, geographic reach, and market share
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Neurological Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Neurological Biomarkers Market